## **Special Issue**

# Novel Insights into Radiopharmaceutics for Cancer Therapy

### Message from the Guest Editors

Targeted radionuclide therapy (TRT) has reached the culmination of translational research with the pivotal NETTER and VISION trials. Patients suffering from metastatic neuroendocrine tumors and metastatic prostate cancer tumors now benefit from this new treatment modality in our departments. However, we should continue and intensify preclinical and clinical research to determine the best place of TRT throughout the various progressive stages of cancer. We should also focus our efforts on deciphering treatment resistance and recurrence mechanisms but also testing novel combinations and dose regimens for targeted radio-/immuno-/chemotherapies. Finally, the design of novel radiopharmaceuticals armed with innovative radionuclides for TRT or for pretherapeutic imaging or radiopharmaceuticals targeting novel molecular signatures of cancer cells might expand the applications of TRT to diseases not currently eligible for TRT and would increase the efficacy of TRT.

### **Guest Editors**

### Dr. Clément Morgat

- 1. Department of Nuclear Medicine, University Hospital of Bordeaux, F-33000 Bordeaux, France
- 2. INCIA, Translational Molecular Imaging Team, University of Bordeaux, F-33000 Bordeaux, France

### Dr. David Kryza

Laboratoire d'Automatique, de Génie des Procédés et de Génie Pharmaceutique, Université Claude Bernard Lyon 1, CNRS UMR 5007, 43 bd 11 Novembre 1918, 69622 Villeurbanne, France

### Deadline for manuscript submissions

closed (31 March 2022)



## **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/91695

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

